The Experts below are selected from a list of 240 Experts worldwide ranked by ideXlab platform
Yiheng Liang - One of the best experts on this subject based on the ideXlab platform.
-
A randomized clinical trial of the efficacy and safety of Terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.
Medical mycology, 2015Co-Authors: Yuxia Zhu, Shangrong Fan, Xiaoping Liu, Yiheng LiangAbstract:Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a Terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the Terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7‐14 days and 30‐35 days following the last dose of therapy. The clinical cure rates in the Terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7‐14 and 60.3% (35/58) and 56.1% (37/66) at day 30‐35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7‐14 and 62.1% (36/58) and 53.0% (35/66) at day 30‐35 (P > .05 for all). Local irritation was the primary adverse event associated with Terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a Terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150 mg) in the treatment of patients with SVVC; as such, Terconazole could be a choice for therapy of this disorder.
Liang Yiheng - One of the best experts on this subject based on the ideXlab platform.
-
A randomized clinical trial of the efficacy and safety of Terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis
medical mycology, 2015Co-Authors: Li Ting, Zhu Yuxia, Fan Shangrong, Liu Xiaoping, Xu Huicong, Liang YihengAbstract:Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a Terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the Terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7-14 days and 30-35 days following the last dose of therapy. The clinical cure rates in the Terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7-14 and 60.3% (35/58) and 56.1% (37/66) at day 30-35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7-14 and 62.1% (36/58) and 53.0% (35/66) at day 30-35 (P > .05 for all). Local irritation was the primary adverse event associated with Terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a Terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150?mg) in the treatment of patients with SVVC; as such, Terconazole could be a choice for therapy of this disorder.? The Author 2015. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000356249800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701SCI(E)PubMed1ARTICLEfanshangrong@163.co
A Chatwani - One of the best experts on this subject based on the ideXlab platform.
-
Terconazole Cream for Non-Candida albicans Fungal Vaginitis " Results of a Retrospective Analysis
2013Co-Authors: G Sood, P Nyirjesy, Velma M. Weitz, A ChatwaniAbstract:Objective: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, Terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of Terconazole cream in women with non-C. albicans vaginitis. Methods: The records of patients who had received a 7-day course of Terconazole cream for culture-proved non-C, albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. Results: Twenty-eight patients received Terconazole cream for non-C, albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received Terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior Terconazole use was not associated with treatment failure (P 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %) patients remained uncured. Conclusions: Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug. Infect. Dis. Obstet. Gynecol
-
Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.
Infectious diseases in obstetrics and gynecology, 2000Co-Authors: G Sood, P Nyirjesy, M V Weitz, A ChatwaniAbstract:Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, Terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of Terconazole cream in women with non-C. albicans vaginitis. The records of patients who had received a 7-day course of Terconazole cream for culture-proved non-C. albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. Twenty-eight patients received Terconazole cream for non-C. albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received Terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior Terconazole use was not associated with treatment failure (P = 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %) patients remained uncured. Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug.
-
Terconazole cream for non-Candida albicans fungal vaginitis: Results of a retrospective analysis
Infectious Diseases in Obstetrics & Gynecology, 2000Co-Authors: G Sood, P Nyirjesy, M V Weitz, A ChatwaniAbstract:Objective: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, Terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of Terconazole cream in women with non-C. albicans vaginitis.
-
Terconazole Cream for Non-Candida albicans Fungal Vaginitis: Results of a Retrospective Analysis
Hindawi Limited, 2000Co-Authors: G Sood, P Nyirjesy, Velma M. Weitz, A ChatwaniAbstract:Objective: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, Terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of Terconazole cream in women with non-C. albicans vaginitis
Yuxia Zhu - One of the best experts on this subject based on the ideXlab platform.
-
A randomized clinical trial of the efficacy and safety of Terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.
Medical mycology, 2015Co-Authors: Yuxia Zhu, Shangrong Fan, Xiaoping Liu, Yiheng LiangAbstract:Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a Terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the Terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7‐14 days and 30‐35 days following the last dose of therapy. The clinical cure rates in the Terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7‐14 and 60.3% (35/58) and 56.1% (37/66) at day 30‐35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7‐14 and 62.1% (36/58) and 53.0% (35/66) at day 30‐35 (P > .05 for all). Local irritation was the primary adverse event associated with Terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a Terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150 mg) in the treatment of patients with SVVC; as such, Terconazole could be a choice for therapy of this disorder.
Li Ting - One of the best experts on this subject based on the ideXlab platform.
-
A randomized clinical trial of the efficacy and safety of Terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis
medical mycology, 2015Co-Authors: Li Ting, Zhu Yuxia, Fan Shangrong, Liu Xiaoping, Xu Huicong, Liang YihengAbstract:Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a Terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the Terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7-14 days and 30-35 days following the last dose of therapy. The clinical cure rates in the Terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7-14 and 60.3% (35/58) and 56.1% (37/66) at day 30-35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7-14 and 62.1% (36/58) and 53.0% (35/66) at day 30-35 (P > .05 for all). Local irritation was the primary adverse event associated with Terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a Terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150?mg) in the treatment of patients with SVVC; as such, Terconazole could be a choice for therapy of this disorder.? The Author 2015. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000356249800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701SCI(E)PubMed1ARTICLEfanshangrong@163.co